CLLS - Cellectis

-

$undefined

N/A

(N/A)

Cellectis NasdaqGM:CLLS Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Location: 8 rue de la Croix Jarry, Paris, 75013, France | Website: https://www.cellectis.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

72.69M

Cash

127.6M

Avg Qtr Burn

N/A

Short % of Float

0.56%

Insider Ownership

3.86%

Institutional Own.

21.49%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
UCART22 Details
Acute lymphoblastic leukemia, Rare genetic disease, Cancer, B-cell acute lymphoblastic leukemia

Phase 1/2

Update

UCART20x22 Details
Cancer, Non-Hodgkin lymphoma

Phase 1/2

Update

UCART123 Details
Cancer, Relapsed/refractory acute myeloid leukemia

Phase 1

Data readout

ALLO-715 Details
Cancer, Multiple myeloma

Failed

Discontinued

ALLO-501 Details
Non-Hodgkin lymphoma, Cancer

Failed

Discontinued

UCART19 (anti-CD19) Details
Cancer, Multiple myeloma, Acute lymphoblastic leukemia

Failed

Discontinued

UCARTCS1 Details
Cancer, Multiple myeloma, Menkes Disease

Failed

Discontinued